163 related articles for article (PubMed ID: 36323507)
1.
Vahdatinia M; Derakhshan F; Da Cruz Paula A; Dopeso H; Marra A; Gazzo AM; Brown D; Selenica P; Ross DS; Razavi P; Zhang H; Weigelt B; Wen HY; Brogi E; Reis-Filho JS; Pareja F
J Clin Pathol; 2023 Dec; 77(1):40-45. PubMed ID: 36323507
[TBL] [Abstract][Full Text] [Related]
2. Nonlobular Invasive Breast Carcinomas with Biallelic Pathogenic CDH1 Somatic Alterations: A Histologic, Immunophenotypic, and Genomic Characterization.
Derakhshan F; Da Cruz Paula A; Selenica P; da Silva EM; Grabenstetter A; Jalali S; Gazzo AM; Dopeso H; Marra A; Brown DN; Ross DS; Mandelker D; Razavi P; Chandarlapaty S; Wen HY; Brogi E; Zhang H; Weigelt B; Pareja F; Reis-Filho JS
Mod Pathol; 2024 Feb; 37(2):100375. PubMed ID: 37925055
[TBL] [Abstract][Full Text] [Related]
3. Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas.
Berrino E; Annaratone L; Bellomo SE; Ferrero G; Gagliardi A; Bragoni A; Grassini D; Guarrera S; Parlato C; Casorzo L; Panero M; Sarotto I; Giordano S; Cereda M; Montemurro F; Ponzone R; Crosetto N; Naccarati A; Sapino A; Marchiò C
Genome Med; 2022 Aug; 14(1):98. PubMed ID: 36038884
[TBL] [Abstract][Full Text] [Related]
4. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
[TBL] [Abstract][Full Text] [Related]
5. A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.
Vasan N; Yelensky R; Wang K; Moulder S; Dzimitrowicz H; Avritscher R; Wang B; Wu Y; Cronin MT; Palmer G; Symmans WF; Miller VA; Stephens P; Pusztai L
Oncologist; 2014 May; 19(5):453-8. PubMed ID: 24710307
[TBL] [Abstract][Full Text] [Related]
6. Genetic alterations and their association with clinicopathologic characteristics in advanced breast carcinomas: focusing on clinically actionable genetic alterations.
Freitag CE; Mei P; Wei L; Parwani AV; Li Z
Hum Pathol; 2020 Aug; 102():94-103. PubMed ID: 32445652
[TBL] [Abstract][Full Text] [Related]
7. Molecular characterisation of cell line models for triple-negative breast cancers.
Grigoriadis A; Mackay A; Noel E; Wu PJ; Natrajan R; Frankum J; Reis-Filho JS; Tutt A
BMC Genomics; 2012 Nov; 13():619. PubMed ID: 23151021
[TBL] [Abstract][Full Text] [Related]
8. Myxoid fibroadenomas differ from conventional fibroadenomas: a hypothesis-generating study.
Lozada JR; Burke KA; Maguire A; Pareja F; Lim RS; Kim J; Gularte-Merida R; Murray MP; Brogi E; Weigelt B; Reis-Filho JS; Geyer FC
Histopathology; 2017 Oct; 71(4):626-634. PubMed ID: 28513873
[TBL] [Abstract][Full Text] [Related]
9. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.
Cheng DT; Mitchell TN; Zehir A; Shah RH; Benayed R; Syed A; Chandramohan R; Liu ZY; Won HH; Scott SN; Brannon AR; O'Reilly C; Sadowska J; Casanova J; Yannes A; Hechtman JF; Yao J; Song W; Ross DS; Oultache A; Dogan S; Borsu L; Hameed M; Nafa K; Arcila ME; Ladanyi M; Berger MF
J Mol Diagn; 2015 May; 17(3):251-64. PubMed ID: 25801821
[TBL] [Abstract][Full Text] [Related]
10. Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients.
Ross DS; Liu B; Schram AM; Razavi P; Lagana SM; Zhang Y; Scaltriti M; Bromberg JF; Ladanyi M; Hyman DM; Drilon A; Zehir A; Benayed R; Chandarlapaty S; Hechtman JF
Ann Oncol; 2020 Aug; 31(8):991-1000. PubMed ID: 32348852
[TBL] [Abstract][Full Text] [Related]
11. RAS/MAPK Pathway Driver Alterations Are Significantly Associated With Oncogenic KIT Mutations in Germ-cell Tumors.
Mata DA; Yang SR; Ferguson DC; Liu Y; Sharma R; Benhamida JK; Al-Ahmadie HA; Chakravarty D; Solit DB; Tickoo SK; Gupta S; Arcila ME; Ladanyi M; Feldman DR; Reuter VE; Vanderbilt CM
Urology; 2020 Oct; 144():111-116. PubMed ID: 32721511
[TBL] [Abstract][Full Text] [Related]
12. Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification.
Ng CK; Martelotto LG; Gauthier A; Wen HC; Piscuoglio S; Lim RS; Cowell CF; Wilkerson PM; Wai P; Rodrigues DN; Arnould L; Geyer FC; Bromberg SE; Lacroix-Triki M; Penault-Llorca F; Giard S; Sastre-Garau X; Natrajan R; Norton L; Cottu PH; Weigelt B; Vincent-Salomon A; Reis-Filho JS
Genome Biol; 2015 May; 16(1):107. PubMed ID: 25994018
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
[TBL] [Abstract][Full Text] [Related]
14. Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases.
Schrijver WAME; Selenica P; Lee JY; Ng CKY; Burke KA; Piscuoglio S; Berman SH; Reis-Filho JS; Weigelt B; van Diest PJ; Moelans CB
Cancer Res; 2018 Jun; 78(12):3112-3121. PubMed ID: 29615433
[TBL] [Abstract][Full Text] [Related]
15. The genomic landscape of metastatic histologic special types of invasive breast cancer.
Pareja F; Ferrando L; Lee SSK; Beca F; Selenica P; Brown DN; Farmanbar A; Da Cruz Paula A; Vahdatinia M; Zhang H; Zoppoli G; Wen HY; Brogi E; Robson ME; Razavi P; Chandarlapaty S; Weigelt B; Reis-Filho JS
NPJ Breast Cancer; 2020; 6():53. PubMed ID: 33083532
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing.
Ross DS; Zehir A; Brogi E; Konno F; Krystel-Whittemore M; Edelweiss M; Berger MF; Toy W; Chandarlapaty S; Razavi P; Baselga J; Wen HY
Mod Pathol; 2019 Jan; 32(1):81-87. PubMed ID: 30158597
[TBL] [Abstract][Full Text] [Related]
17. The Genomic Landscape of Male Breast Cancers.
Piscuoglio S; Ng CK; Murray MP; Guerini-Rocco E; Martelotto LG; Geyer FC; Bidard FC; Berman S; Fusco N; Sakr RA; Eberle CA; De Mattos-Arruda L; Macedo GS; Akram M; Baslan T; Hicks JB; King TA; Brogi E; Norton L; Weigelt B; Hudis CA; Reis-Filho JS
Clin Cancer Res; 2016 Aug; 22(16):4045-56. PubMed ID: 26960396
[TBL] [Abstract][Full Text] [Related]
18. Genomic alterations and radioresistance in breast cancer: an analysis of the ProfiLER protocol.
Bernichon E; Vallard A; Wang Q; Attignon V; Pissaloux D; Bachelot T; Heudel PE; Ray-Coquard I; Bonnet E; de la Fouchardière A; Faure C; Chopin N; Beurrier F; Racadot S; Sunyach MP; Rancoule C; Perol D; Corset V; Agrapart V; Tinquaut F; Blay JY; Magné N; Trédan O
Ann Oncol; 2017 Nov; 28(11):2773-2779. PubMed ID: 28945826
[TBL] [Abstract][Full Text] [Related]
19. ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC).
Ferrando L; Vingiani A; Garuti A; Vernieri C; Belfiore A; Agnelli L; Dagrada G; Ivanoiu D; Bonizzi G; Munzone E; Lippolis L; Dameri M; Ravera F; Colleoni M; Viale G; Magnani L; Ballestrero A; Zoppoli G; Pruneri G
PLoS Genet; 2023 Jan; 19(1):e1010563. PubMed ID: 36595552
[TBL] [Abstract][Full Text] [Related]
20. Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers.
Fumagalli D; Wilson TR; Salgado R; Lu X; Yu J; O'Brien C; Walter K; Huw LY; Criscitiello C; Laios I; Jose V; Brown DN; Rothé F; Maetens M; Zardavas D; Savas P; Larsimont D; Piccart-Gebhart MJ; Michiels S; Lackner MR; Sotiriou C; Loi S
Ann Oncol; 2016 Oct; 27(10):1860-6. PubMed ID: 27672107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
